Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up

• Prif Awduron: Susanne K. Kjaer (Awdur), Mari Nygård (Awdur), Karin Sundström (Awdur), Christian Munk (Awdur), Sophie Berger (Awdur), Mensur Dzabic (Awdur), Katrin Elisabeth Fridrich (Awdur), Marianne Waldstrøm (Awdur), Sveinung Wergeland Sørbye (Awdur), Oliver Bautista (Awdur), Thomas Group (Awdur), Alain Luxembourg (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2021-04-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

A long-term follow-up (LTFU) of the nine-valent human papillomavirus (9vHPV) vaccine efficacy study in young women aged 16-26 years was initiated to evaluate if vaccine effectiveness for up to 14 years post-vaccination will remain above 90%. Vaccine effectiveness is measured as percent reduction in...